

CLINICAL **P**HARMACOLOGY *and* **T**HERAPEUTICS

Editor

Walter Modell, M.D.

Associate Editor

Marcus M. Reidenberg, M.D.

Editorial Board

- | | |
|---------------------------------|-------------------------------|
| Alvito P. Alvares, Ph.D. | Stanley A. Kaplan, Ph.D. |
| Wilbert S. Aronow, M.D. | Attallah Kappas, M.D. |
| Arthur J. Atkinson, Jr., M.D. | Arthur S. Keats, M.D. |
| Daniel L. Azarnoff, M.D. | Richard H. Kessler, M.D. |
| Frank M. Berger, M.D., D.Sc. | Kenneth G. Kohlstaedt, M.D. |
| Karl H. Beyer, Jr., M.D., Ph.D. | Henn Kutt, M.D. |
| Hylan A. Bickerman, M.D. | Louis Lasagna, M.D. |
| Terrence F. Blaschke, M.D. | Louis Lemberger, M.D., Ph.D. |
| Donald B. Calne, M.D. | Gerhard Levy, Pharm.D. |
| Edward A. Carr, Jr., M.D. | T. A. Loomis, M.D., Ph.D. |
| Allan H. Conney, Ph.D. | David T. Lowenthal, M.D. |
| T. S. Danowski, M.D. | Daniel S. Lukas, M.D. |
| Arthur C. DeGraff, M.D. | Arno G. Motulsky, M.D. |
| Peter Dineen, M.D. | Alan S. Nies, M.D. |
| Edward F. Domino, M.D. | R. K. Richards, M.D. |
| Alvan R. Feinstein, M.D. | David G. Shand, M.B., Ph.D. |
| Vladimir Fencl, M.D. | Albert Sjoerdsma, M.D., Ph.D. |
| Robert B. Forney, Ph.D. | Jay Tepperman, M.D. |
| Emil Frei, III, M.D. | Max Tishler, Ph.D. |
| Milo Gibaldi, Ph.D. | Leroy D. Vandam, M.D. |
| Norton J. Greenberger, M.D. | Elliot S. Vesell, M.D. |
| Leo E. Hollister, M.D. | Louis Weinstein, M.D. |
| Bartholomew P. Hsi, Ph.D. | John G. Wagner, Ph.D. |
| Murray E. Jarvik, M.D. | E. Leong Way, Ph.D. |
| Ernest Jawetz, M.D., Ph.D. | |

Volume 30, July-December, 1981
The C. V. Mosby Company, St. Louis

Volume 30
Copyright © 1981 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 30

Author index

A

- Ananonen L: *see* Shand et al, 701
Abeysekera G: *see* Brodie et al, 363
Actor P: *see* Pitkin et al, 587
Akimoto T: *see* Nomura et al, 177
Alexander F: *see* Pitkin et al, 587
Alford RH: *see* Hawkins et al, 468
Aliendres R: *see* Velasco et al, 158
Alken RG: *see* Haeghele et al, 210
Allonen H, Ziegler G, Klotz U: Midazolam kinetics, 653
Amsterdam EA: *see* Harris et al, 765
Andreasen PB: *see* Døssing and Andreasen, 101
Andrews-Figueroa P: *see* Velasco et al, 158
Arita T: *see* Nomura et al, 177
Asbury MJ: *see* McInnes et al, 218
Ashley JJ: *see* Freedman et al, 644
Awadzi K: *see* Edwards et al, 551
Axthelm T: *see* Kirch et al, 429

B

- Baer-Weiss V: *see* Gritz et al, 201
Ballard RH: *see* Miller et al, 343
Barchowsky A: *see* Routledge et al, 154
Barkley R: *see* Bauer et al, 35
Bauer JH, Brooks CS, Weinstein I, Wilcox HH, Heimberg M, Burch RN, Barkley R: Effects of diuretic and propranolol on plasma lipoprotein lipids, 35
Bekersky I: *see* Colburn et al, 559
Benet LZ: *see* Smith et al, 105
Benowitz NL: *see* Gritz et al, 201
—*see* Pond et al, 183
Bergstrom RF, Kay DR, Harkcom TM, Wagner JG: Penicillamine kinetics in normal subjects, 404
Bertilsson L: *see* Mellström et al, 189
Bianchine JR: *see* Foulds et al, 693

July, pp. 1-148; August, pp. 149-282; September, pp. 283-428; October, pp. 429-580; November, pp. 581-708; December, pp. 709-838.

- Birkett DJ: *see* Grygiel and Birkett, 491
Bixler EO: *see* Kales et al, 194
Björnsson TD: *see* Brown et al, 636
Blumenthal HP: *see* Colburn et al, 559
Bobik A, Jennings G, Skews H, Esler M, McLean A: Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension, 673
—*see* Jackman et al, 291
—*see* McLean et al, 31
Bochner F, Graham GG, Cham BE, Imhoff DM, Haavisto TM: Salicylate metabolite kinetics after several salicylates, 266
Bodey GP: *see* Estey et al, 398
Boelaert J: *see* Hallynck et al, 414
Boobis AR: *see* Brodie et al, 363
Boyd ND: *see* Kinniburgh and Boyd, 276
Branch RA: *see* Verbeeck et al, 619
Bravo EL: *see* Fouad et al, 782
Breckenridge AM: *see* Edwards et al, 551
Brodie MJ, Boobis AR, Hillyard CJ, Abeysekera G, MacIntyre I, Park BK: Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity, 363
Brooks CS: *see* Bauer et al, 35
Brown AS: *see* Rickels et al, 95
Brown JE, Kitchell BB, Björnsson TD, Shand DG: The artifactual nature of heparin-induced drug protein-binding alterations, 636
Brown JL: *see* Chrysant et al, 600
Brown N: *see* Estey et al, 398
Buch J: *see* Waldorff et al, 172
Buntinx AP: *see* Tobert et al, 385
Burch RN: *see* Bauer et al, 35
Buskin JN: *see* Williams et al, 226
Busto U: *see* Naranjo et al, 239
- C
- Campbell SC, Lauver GL, Cobb RB Jr: Central ventilatory depression by oral propranolol, 758
Carruthers SG, Twum-Barima Y: Measurement of partial agonist activity of pindolol, 581
Cato AE: *see* Zusman et al, 251

- Cavanaugh JH: *see* Stoll et al, 605
 Cham BE: *see* Bochner et al, 266
 Chiang ST: *see* Murray et al, 805
 Chrysant SG, Miller RP, Brown JL, Danisa K: Long-term hemodynamic and metabolic effects of trimazosin in essential hypertension, 600
 Chu L-C: *see* Hogan et al, 729
 Clarke JM: *see* McInnes et al, 218
 Clements JA: *see* Holt et al, 232
 Clifton G: *see* Cruz et al, 57
 Cobb RB Jr: *see* Campbell et al, 758
 Cohen D: *see* Rickels et al, 95
 Colburn WA, Bekersky I, Blumenthal HP: Dietary saccharin kinetics, 559
 Cole AFD: *see* Elvin et al, 455
 Connor JD: *see* de Miranda et al, 662
 Conrad KA, Lee SM: Clodronate kinetics and dynamics, 114
 Conradi EC: *see* Walle et al, 790
 Copeland JG: *see* Plachetka et al, 745
 Crow JW: *see* Zusman et al, 251
 Cruz F, O'Neill WM Jr, Clifton G, Wallin JD: Effects of labetalol and methyldopa on renal function, 57
- D**
- Dahlström B: *see* Säwe et al, 629
 Daneels R: *see* Hallynck et al, 414
 Danisa K: *see* Chrysant et al, 600
 Davies RO: *see* Green et al, 378
 DeMaria AN: *see* Harris et al, 765
 de Miranda P, Good SS, Laskin OL, Krasny HC, Connor JD, Leitman PS: Disposition of intravenous radioactive acyclovir, 662
 De Rosa F: *see* Hallynck et al, 414
 DeSchepper P: *see* Tobert et al, 385
 Dettli L: *see* Hallynck et al, 414
 Dhahir P: *see* Rubin et al, 258
 Dillenhofer RL: *see* Giles et al, 724
 Diven W: *see* Garzone et al, 86
 Divoll M: *see* Greenblatt et al, 475
 Dollery CT: *see* FitzGerald et al, 164
 Domecq C: *see* Naranjo et al, 239
 Dorph-Pedersen A: *see* Pedersen et al, 311
 Døssing M, Andreasen PB: Ethanol and antipyrine clearance, 101
 Dubb J: *see* Pitkin et al, 587
 Dudley FJ: *see* McLean et al, 31
 Dumbrell M: *see* Sandor et al, 390
 Dustan HP: *see* Wilkins et al, 752
 Dziedzic SW: *see* Gorkin et al, 739
 Dziubinski J: *see* Mackenzie et al, 436
- E**
- Easler ME: *see* Ellinwood et al, 534
 Edwards G, Awadik K, Breckenridge AM, Gilles HM, Orme ML'E, Ward SA: Diethylcarbamazine disposition in patients with onchocerciasis, 551
 Egeblad H: *see* Waldorff et al, 172
- Ehrlich S: *see* Pitkin et al, 587
 Eliovich F: *see* Gorkin et al, 739
 Elkayam U, Mathur M, Frishman W, LeJemtel T, Strom J, Sonnenblick EH: Dynamic responses to continuous use of prazosin and hydralazine in patients with refractory heart failure, 23
 Ellinwood EH Jr, Linnoila M, Easler ME, Molter DW: Onset of peak impairment after diazepam and after alcohol, 534
 Elvin AT, Cole AFD, Pieper JA, Rolbin SH, Lalka D: Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination, 455
 Engle MA: *see* Lindsay et al, 735
 Esler M: *see* Bobik et al, 673
 Estey EH, Weaver SS, LeBlanc BM, Brown N, Ho DH, Bodey GP: Ceforanide kinetics, 398
- F**
- Fagan TC: *see* Walle et al, 790
 Familiar R: *see* Pitkin et al, 587
 Fanizza AM: *see* Novick et al, 353
 Feinstein AR: Clinical biostatistics LVI. The t test and the basic ethos of parametric statistical inference (Conclusion), 133
 —Clinical biostatistics LVII. A glossary of neologisms in quantitative clinical science, 564
 Fillastre JP: *see* Hallynck et al, 414
 Fink M, Irwin P: Pharmacoelectroencephalographic study of brotizolam, a novel hypnotic, 336
 Fish A: *see* Pickles et al, 303
 Fitzgerald GA, Hossman V, Dollery CT: Norepinephrine release in essential hypertension, 164
 Fouad F, Tarazi RC, Bravo EL: Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy, 782
 Foulds G, O'Brien MM, Bianchine JR, Gabbay KH: Kinetics of an orally absorbed aldose reductase inhibitor, sorbinil, 693
 Freedman SB, Richmond DR, Ashley JJ, Kelly DT: Verapamil kinetics in normal subjects and patients with coronary spasm, 644
 Frishman W: *see* Elkayam et al, 23
 Frisk-Holmberg M, Jorfeldt L, Juhlin-Dannfelt A: Metabolic effects in muscle during antihypertensive therapy with β_1 - and β_1/β_2 -adrenoceptor blockers, 611
 Frölich JC: *see* Reimann and Frölich, 348
 Fuller R, Hoppel C, Ingalls ST: Furosemide kinetics in patients with hepatic cirrhosis with ascites, 461
- G**
- Gabbay KH: *see* Foulds et al, 693
 Gaffney TE: *see* Walle et al, 790
 Gambertoglio JG: *see* Smith et al, 105

- Ganguly A, Weinberger MH: Triamterene-thiazide combination: alternative therapy for primary aldosteronism, 246
- Garland WA: *see* Miller et al, 343
- Garzone P, Lyon J, Yu VL, Zuraleff J, Diven W, Pasculle W: Steady-state moxalactam kinetics: comparisons with other cephalosporins, 86
- Gelb AM: *see* Novick et al, 353
- Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dilenkeroff RL: Short-term effects of intravenous clonidine in congestive heart failure, 724
- Gilles HM: *see* Edwards et al, 551
- Glickstein S: *see* Weintraub et al, 149
- Gobuty AH: *see* Wahl et al, 506
- Goldberger V: *see* Hager et al, 283
- Goldstein M: *see* Leibowitz et al, 719
- Good SS: *see* de Miranda et al, 662
- Gopinathan G: *see* Leibowitz et al, 719
- Gorkin JU, Eliovich F, Dziedzic SW, Krakoff LR: Addition of acebutolol to diuretics in hypertension, 739
- Graham GG: *see* Bochner et al, 266
- Grahnén A, Seideman P, Lindström B, Haglund K, von Bahr C: Prazosin kinetics in hypertension, 439
- see* Seideman et al, 447
- Graves PE: *see* Hager et al, 594
- Gray JD: *see* Renton et al, 422
- Green D, Davies RO, Holmes GI, Kohl H, Lee RB, Reynolds N, Schmid FR, Ts'ao C-H: Effects of diflunisal on platelet function and fecal blood loss, 378
- Greenblatt DJ, Divoll M, Harmatz JS, MacLaughlin DS, Shader RI: Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs, 475
- see* Narango et al, 239
- Griffiths RR: *see* Henningfield and Griffiths, 497
- Gritz ER, Baer-Weiss V, Benowitz NL, Van Vunakis H, Jarvik ME: Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users, 201
- Grove J: *see* Haegele et al, 210
- Grygiel JJ, Birkett DJ: Cigarette smoking and theophylline clearance and metabolism, 491
- H*
- Haavisto TM: *see* Bochner et al, 266
- Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J: Kinetics of α -difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase, 210
- Hager WD, Mayersohn M, Graves PE: Digoxin bioavailability during quinidine administration, 594
- Pieniaszek HJ Jr, Perrier D, Mayersohn M, Goldberger V: Assessment of beta-blockade with propranolol, 283
- Haglund K: *see* Seideman et al, 447
- Hall TLP: *see* Tobert et al, 385
- Hallynck T, Soep HH, Thomis J, Boelaert J, Daneels R, Fillastre JP, De Rosa F, Rubinstein E, Hatala M, Spousta J, Dettli L: Prediction of creatinine clearance from serum creatinine concentration based on lean body mass, 414
- Hammill SC: *see* Shand et al, 701
- Hansen PB: *see* Waldorff et al, 172
- Harapat S: *see* Kates et al, 44
- Harkcom TM: *see* Bergstrom et al, 404
- Harmatz JS: *see* Greenblatt et al, 475
- Harris FJ, Tonkin M, Pratt C, DeMaria AN, Amsterdam EA, Mason DT: Short- and long-term therapy of mild essential hypertension with timolol, 765
- Harris H: *see* Rickels et al, 95
- Harrison DC: *see* Kates et al, 44
- Harrison IR: *see* McInnes et al, 218
- Hasday JD: *see* Weintraub et al, 528
- Hata T: *see* Ogihara et al, 328
- Hatala M: *see* Hallynck et al, 414
- Hawkins SS, Alford RH, Stone WJ, Smyth R, Pfleffer M: Ceforanide kinetics in renal insufficiency, 468
- Heading RC: *see* Holt et al, 232
- Heimberg M: *see* Bauer et al, 35
- Hemberger JA: *see* McGraw et al, 321
- Henningfield JE, Griffiths RR: Cigarette smoking and subjective responses: effects of d-amphetamine, 497
- Hernández-Pieretti O: *see* Velasco et al, 158
- Hillyard CJ: *see* Brodie et al, 363
- Ho DH: *see* Estey et al, 398
- Hogan MJ, Wallin JD, Chu L-C: Plasma clonidine concentration and pharmacologic effect, 729
- Holmes GI: *see* Green et al, 378
- Holt S, Heading RC, Clements JA, Tothill P, Prescott LF: Acetaminophen absorption and metabolism in celiac disease and Crohn's disease, 232
- Hoppel C: *see* Fuller et al, 461
- Hossman V: *see* FitzGerald et al, 164
- Huber PB: *see* Tobert et al, 385
- Huemel M: *see* Kampf et al, 77
- Hung OR: *see* Renton et al, 422
- Hurovitz A: *see* Rickels et al, 95
- Hvidt S: *see* Pedersen et al, 311
- I*
- Imhoff DM: *see* Bochner et al, 266
- Ingalls ST: *see* Fuller et al, 461
- Irwin P: *see* Fink and Irwin, 336
- Isbister C: *see* McLean et al, 31
- Iteld BJ: *see* Giles et al, 724
- J*
- Jackman GP, McLean AJ, Jennings GL, Bobik A: No stereoselective first-pass hepatic extraction of propranolol, 291

- Jacob P: *see* Pond et al, 183
 Jacobson EJ, Zahrowski JJ, Nissensohn AR: Moxalactam kinetics in hemodialysis, 487
 Jacoby EH: *see* Manchester and Jacoby, 687
 Jacoby JA: *see* Kales et al, 194
 Janecek E: *see* Naranjo et al, 239
 —*see* Robinson et al, 71
 Jarvik ME: *see* Gritz et al, 201
 Jennings G: *see* Bobik et al, 673
 Jennings GL: *see* Jackman et al, 291
 Jones RM: *see* Williams et al, 226
 Jorfeldt L: *see* Frisk-Holmberg et al, 611
 Juhlin-Dannfelt A: *see* Frisk-Holmberg et al, 611
- K*
- Kales A, Scharf MB, Bixler EO, Schweitzer PK, Jacoby JA, Soldatos CR: Dose-response studies of quazepam, 194
 Kampf D, Huempel M, Lerche U, Kessel M: Effects of uremia and hemodialysis on lormetazepam disposition, 77
 Kates RE, Keefe DLD, Schwartz J, Harapat S, Kirsten EB, Harrison DC: Verapamil disposition kinetics in chronic atrial fibrillation, 44
 Kay DC: *see* Pickworth et al, 796
 Kay DR: *see* Bergstrom et al, 404
 Keefe DLD: *see* Kates et al, 44
 Kelly DT: *see* Freedman et al, 644
 Kessel M: *see* Kampf et al, 77
 Kesseler KM, Perez GO: Decreased quinidine plasma protein binding during hemodialysis, 121
 Khouri V: *see* Sandor et al, 390
 Kinniburgh DW, Boyd ND: Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins, 276
 Kirch W, Schäfer-Korting M, Axthelm T, Köhler H, Mutschler E: Interaction of atenolol with furosemide and calcium and aluminum salts, 429
 Kirsten EB: *see* Kates et al, 44
 Kitchell BB: *see* Brown et al, 636
 Kjagård H: *see* Waldorff et al, 172
 Klitgaard NA: *see* Pedersen et al, 311
 Klotz U, Reimann I: Elevation of steady-state diazepam levels by cimetidine, 513
 —*see* Allonen et al, 653
 Kober G: *see* Woodcock et al, 52
 Koch-Weser J: *see* Haegele et al, 210
 Koepke HH: *see* Murray et al, 805
 Kohl H: *see* Green et al, 378
 Köhler H: *see* Kirch et al, 429
 Krakoff LR: *see* Gorkin et al, 739
 Krasny HC: *see* de Miranda et al, 662
 Kreek MJ: *see* Novick et al, 353
 Kretschmar KM: *see* Pond and Kretschmar, 680
 Kuhlmann J, Zilly W, Wilke J: Effects of cytostatic drugs on plasma level and renal excretion of β -acetyldigoxin, 518
- Kumahara Y: *see* Ogihara et al, 328
 Kupersmith M: *see* Leibowitz et al, 719
- L*
- Lalka D: *see* Elvin et al, 455
 Lasagna L: *see* Weintraub et al, 149
 Laskin OL: *see* de Miranda et al, 662
 Lauver GL: *see* Campbell et al, 758
 Lebert PA, MacLeod SM, Mahon WA, Soldin SJ, Vandenberghe HM: Ranitidine kinetics and dynamics. I. Oral dose studies, 539
 —Mahon WA, MacLeod SM, Soldin SJ, Vandenberghe HM: Ranitidine kinetics and dynamics. II. Intravenous dose studies and comparison with cimetidine, 545
 LeBlanc BM: *see* Estey et al, 398
 Lee RB: *see* Green et al, 378
 Lee SM: *see* Conrad and Lee, 114
 Leberman A: *see* Leibowitz et al, 719
 Leibowitz M, Leberman A, Goldstein M, Neophytides A, Kupersmith M, Gopinathan G, Mehl S: Cardiac effects of pergolide, 719
 Leitman PS: *see* de Miranda et al, 662
 LeJemtel T: *see* Elkayam et al, 23
 Lemberger L: *see* Rubin et al, 258
 Lerche U: *see* Kampf et al, 77
 Levine LS: *see* Rikkind et al, 127
 Levy RH: *see* Miller et al, 343
 Lin M-S: *see* Shepherd et al, 773
 Lindsay LA, Engle MA, Reidenberg MM: Maturation and renal digoxin clearance, 735
 Lindenbaum EJ: *see* Rickels et al, 95
 Lindenbaum J, Long R, Wenger T, Mallis G, Cato A: Lack of difference in digoxin urinary excretion with two intravenous infusion rates, 317
 Lindström B: *see* Grahnén et al, 439
 Linnoila M: *see* Ellinwood et al, 534
 Lockwood D: *see* Weintraub et al, 528
 Long R: *see* Lindenbaum et al, 317
 Ludden T: *see* Shepherd et al, 773
 Ludwick BT: *see* Miller et al, 343
 Lukert BP: *see* Wahl et al, 506
 Lyon J: *see* Garzone et al, 86
- M*
- McGraw BF, Hemberger JA, Smith AL, Schroeder JS: Variability of exercise performance during long-term placebo treatment, 321
 McInnes GT, Shelton JR, Asbury MJ, Harrison IR, Clarke JM, Ramsay LE, Venning GR: Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison, 218
 MacIntyre I: *see* Brodie et al, 363
 Mackenzie TB, Popkin MK, Dziubinski J, Sheppard JR: Effects of caffeine withdrawal on isoproterenol-stimulated cyclic adenosine monophosphate, 436
 MacLaughlin DS: *see* Greenblatt et al, 475

- McLean A: *see* Bobik et al, 673
McLean AJ, Isbister C, Bobik A, Dudley FJ: Reduction of first-pass hepatic clearance of propranolol by food, 31
—*see* Jackman et al, 291
MacLeod CM: *see* Stoll et al, 605
MacLeod SM: *see* Lebert et al, 539, 545
McNay J: *see* Shepherd et al, 773
Mahon WA: *see* Lebert et al, 539, 545
Mallis G: *see* Lindenbaum et al, 317
Manchester DK, Jacoby EH: Sensitivity of human placental monooxygenase activity to maternal smoking, 687
Maruyama A: *see* Ogihara et al, 328
Mason DT: *see* Harris et al, 765
Mathur M: *see* Elkayam et al, 23
Mautner RK: *see* Giles et al, 724
Mayersohn M: *see* Hager et al, 283, 594
Mehl S: *see* Leibowitz et al, 719
Meisinger MAP: *see* Tobert et al, 385
Mellström B, Bertilsson L, Säwe J, Schulz H-U, Sjöqvist F: E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation, 189
Mikami H: *see* Ogihara et al, 328
Miller ME, Garland WA, Min BH, Ludwick BT, Ballard RH, Levy RH: Clonazepam acetylation in fast and slow acetylators, 343
Miller RF: *see* Chrysant et al, 600
Min BH: *see* Miller et al, 343
Minami M: *see* Nomura et al, 177
Mitchell HC, Pettinger WA: Clonidine and prazosin effects in hyperadrenergic vasodilator-treated and β -blocker-treated patients, 297
Miyazaki K: *see* Nomura et al, 177
Modell W: On the significance of significant, 1 (Editorial)
Molter DW: *see* Ellinwood et al, 534
Morillo J: *see* Velasco et al, 158
Mullie A: *see* Tobert et al, 385
Murray TG, Chiang ST, Koepke HH, Walker BR: Renal disease, age, and oxazepam kinetics, 805
Musgrave G: *see* Shepherd et al, 773
Mutschler E: *see* Kirch et al, 429
- N*
- Nahata M, Powell DA: Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate, 368
Naka T: *see* Ogihara et al, 328
Nakamaru M: *see* Ogihara et al, 328
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions, 239
Neider GL: *see* Pickworth et al, 796
Neophytides A: *see* Leibowitz et al, 719
New MI: *see* Rifkind et al, 127
Nielsen-Kudsk F: *see* Pedersen et al, 311
- Nissenson AR: *see* Jacobson et al, 487
Nomura A, Yasuda H, Minami M, Akimoto T, Miyazaki K, Arita T: Effect of furosemide in congestive heart failure, 177
Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ: Methadone disposition in patients with chronic liver disease, 353
- O*
- O'Brien MM: *see* Foulds et al, 693
Oexmann M-J: *see* Walle et al, 790
Ogihara T, Maruyama A, Hata T, Mikami H, Nakamaru M, Naka T, Ohde H, Kumahara Y: Hormonal responses to long-term converting enzyme inhibition in hypertensive patients, 328
Ohde H: *see* Ogihara et al, 328
O'Neill WM Jr: *see* Cruz et al, 57
Oparil S: *see* Wilkins et al, 752
Orme ML'E: *see* Edwards et al, 551
- P*
- Paalzow L: *see* Säwe et al, 629
Pareira J: *see* Rifkind et al, 127
Park BK: *see* Brodie et al, 363
Pasculle W: *see* Garzone et al, 86
Passananti GT: *see* Piroli et al, 810
Pedersen KE, Dorph-Pedersen A, Hvistendahl S, Klitgaard NA, Nielsen-Kudsk F: Digoxin-verapamil interaction, 311
Perez GO: *see* Kessler and Perez, 121
Perrier D: *see* Hager et al, 283
Perucca E: *see* Pickles et al, 303
Pettinger WA: *see* Mitchell and Pettinger, 297
Pfeffer M: *see* Hawkins et al, 468
Pickles H, Perucca E, Fish A, Richens A: Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor, 303
Pickworth WB, Neider GL, Kay DC: Morphine-like arousal by methadone during sleep, 796
Pieniaszek HJ Jr: *see* Hager et al, 283
Pieper JA: *see* Elvin et al, 455
Piroli RJ, Passananti GT, Shively C, Vesell ES: Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia, 810
Pitkin D, Dubb J, Actor P, Alexander F, Ehrlich S, Familiar R, Stote R: Kinetics and renal handling of cefonicid, 587
Plachetka JR, Salomon NW, Copeland JG: Plasma propranolol before, during, and after cardiopulmonary bypass, 745
Pond SM, Kretschmar KM: Effect of phenytoin on meperidine clearance and normeperidine formation, 680
—Tong T, Benowitz NL, Jacob P, Rigid J: Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects, 183

- Popkin MK: *see* Mackenzie et al, 436
 Powell DA: *see* Nahata and Powell, 368
 Pratt C: *see* Harris et al, 765
 Prescott LF: *see* Holt et al, 232
 Pritchett EC: *see* Shand et al, 701
- R*
- Ramírez A: *see* Velasco et al, 158
 Ramsay LE: *see* McInnes et al, 218
 Rane A: *see* Säwe et al, 629
 Reichgott MJ: Minoxidil and pericardial effusion: an idiosyncratic reaction, 64
 Reidenberg MM: *see* Lindsay et al, 735
 Reimann I: *see* Klotz and Reimann, 513
 Reimann IW, Frölich JC: Effects of diclofenac on lithium kinetics, 348
 Reitbrock N: *see* Woodcock et al, 52
 Renton KW, Gray JD, Hung OR: Depression of theophylline elimination by erythromycin, 422
 Reynolds N: *see* Green et al, 378
 Richens A: *see* Pickles et al, 303
 Richmond DR: *see* Freedman et al, 644
 Rickels K, Brown AS, Cohen D, Harris H, Hurowitz A, Lindenbaum EJ, Ross HA, Weinstock R, Wiseman K, Zal M: Clotiazepam and diazepam in anxiety, 95
 Rifkind AB, Saenger P, Levine LS, Pareira J, New MI: Effects of growth hormone on antipyrene kinetics in children, 127
 Rigod J: *see* Pond et al, 183
 Roberts EA: *see* Naranjo et al, 239
 Robinson GM, Sellers EM, Jenecek E: Barbiturate and hypnotosedative withdrawal by a multiple oral phenobarbital loading dose technique, 71
 Rognoni PA: *see* Giles et al, 724
 Rolbin SH: *see* Elvin et al, 455
 Ross HA: *see* Rickels et al, 95
 Routledge PA, Shand DG, Barchowsky A, Wagner G, Stargel WW: Relationship between α_1 -acid glycoprotein and lidocaine disposition in myocardial infarction, 154
 Rubin A, Lemberger L, Dahir P: Physiologic disposition of pergolide, 258
 Rubinstein E: *see* Hallynck et al, 414
 Ruiz I: *see* Naranjo et al, 239
- S*
- Saenger P: *see* Rifkind et al, 127
 Salomon NW: *see* Plachetka et al, 745
 Sandor P, Sellers EM, Dumbrell M, Khoury V: Effect of short and long-term alcohol use on phenytoin kinetics in chronic alcoholics, 390
—see Naranjo et al, 239
 Säwe J, Dahlström B, Paalzow L, Rane A: Morphine kinetics in cancer patients, 629
—see Mellström et al, 189

- Schäfer-Körting M: *see* Kirch et al, 429
 Scharf MB: *see* Kales et al, 194
 Schechter PJ: *see* Haeghebaert et al, 210
 Schmid FR: *see* Green et al, 378
 Schroeder JS: *see* McGraw et al, 321
 Schulz H-U: *see* Mellström et al, 189
 Schulz W: *see* Woodcock et al, 52
 Schwartz J: *see* Kates et al, 44
 Schweitzer PK: *see* Kales et al, 194
 Seideman P, Grahnén A, Haglund K, Lindström B, von Vahr C: Prazosin dynamics in hypertension: relationship to plasma concentration, 447
—see Grahnén et al, 439
 Sellers EM: *see* Naranjo et al, 239
—see Robinson et al, 71
—see Sandor et al, 390
 Shader RI: *see* Greenblatt et al, 475
 Shand DG, Hammill SC, Aanonsen L, Pritchett EC: Reduced verapamil clearance during long-term oral administration, 701
—see Brown et al, 636
—see Routledge et al, 154
 Shelton JR: *see* McInnes et al, 218
 Shepherd A, Lin M-S, McNay J, Ludden T, Musgrave G: Determinants of response to intravenous hydralazine in hypertension, 773
 Sheppard JR: *see* Mackenzie et al, 810
 Shively C: *see* Piroli et al, 810
 Sjöerdsma A: Suicide enzyme inhibitors as potential drugs, 3 (Commentary)
 Sjöqvist F: *see* Mellström et al, 189
 Skewis H: *see* Bobik et al, 673
 Smith AL: *see* McGraw et al, 321
 Smith DE, Gambertoglio JG, Vincenti F, Benet LZ: Furosemide kinetics and dynamics after kidney transplant, 105
 Smith LR: *see* Wilkins et al, 752
 Smyth R: *see* Hawkins et al, 468
 Soep HH: *see* Hallynck et al, 414
 Soldatos CR: *see* Kales et al, 194
 Soldin SJ: *see* Lebert et al, 539, 545
 Sonnenblick EH: *see* Elkayam et al, 23
 Spousta J: *see* Hallynck et al, 414
 Stargel WW: *see* Routledge et al, 154
 Steinness E: *see* Waldorff et al, 172
 Stenger RJ: *see* Novick et al, 353
 Stoll RW, Cavanaugh JH, MacLeod CM: Beta-blocking effect of single oral doses of carteolol, 605
 Stone WJ: *see* Hawkins et al, 468
 Stote R: *see* Pitkin et al, 587
 Strom J: *see* Elkayam et al, 23
- T*
- Tarazi RC: *see* Fouad et al, 782
 Taves DR: *see* Weintraub et al, 528
 Thomis J: *see* Hallynck et al, 414
 Tjandramaga TB: *see* Tobert et al, 385

- Tobert JA, DeSchepper P, Tjandramaga TB, Mullie A, Buntinx AP, Meisinger MAP, Huber PB, Hall TLP, Yeh KC: Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states, 385
Tolkoff-Rubin N: *see Zusman et al.*, 251
Tong T: *see Pond et al.*, 183
Tonkin M: *see Harris et al.*, 765
Tothill P: *see Holt et al.*, 232
Ts'ao CH: *see Green et al.*, 378
Twum-Barima Y: *see Carruthers and Twum-Barima*, 581

U

- Upton RA: *see Williams et al.*, 226
Urbina-Quintana A: *see Velasco et al.*, 158

V

- Van Vunakis H: *see Gritz et al.*, 201
Vandenbergh HM: *see Lebert et al.*, 539, 545
Velasco M, Andrews-Figueroa P, Ramírez A, Morillo J, Urbina-Quintana A, Aliendres R, Hernández-Pieretti O: Systemic and cardiac hemodynamic interactions between clonidine and minoxidil, 158
Venning GR: *see McInnes et al.*, 218
Verbeeck RK, Branch RA, Wilkinson GR: Meperidine disposition in man: influence of urinary pH and route of administration, 619
Vesell ES: *see Piroli et al.*, 801
Vincenti F: *see Smith et al.*, 105
von Bahr C: *see Grahnén et al.*, 439
—*see Seideman et al.*, 447

W

- Wagner G: *see Routledge et al.*, 154
Wagner JG: *see Bergstrom et al.*, 404
Wahl TO, Gobuty AH, Lukert BP: Long-term anticonvulsant therapy and intestinal calcium absorption, 506
Waldorff S, Hansen PB, Kjagård H, Buch J, Egebäld H, Steiness E: Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride, 172
Walker BR: *see Murray et al.*, 805
Walle T, Fagan TC, Walle UK, Oexmann M-J, Conradi EC, Gaffney TE: Food-induced increase in propranolol bioavailability—relationship to protein and effects on metabolites, 790

- Walle UK: *see Walle et al.*, 790
Wallin JD: *see Cruz et al.*, 57
—*see Hogan et al.*, 729
Walter U: Red blood cell sodium and potassium after hydrochlorothiazide, 373
—Effect of ouabain and furosemide on erythrocyte sodium and phosphate transport, 709
Ward SA: *see Edwards et al.*, 551
Weaver SS: *see Estey et al.*, 398
Weinberger MH: *see Ganguly and Weinberger*, 246
Weinstein I: *see Bauer et al.*, 35
Weinstock R: *see Rickels et al.*, 95
Weintraub M, Glickstein S, Lasagna L: Estrogen patient package insert: medication acceptance despite negative attitudes, 149 (Commentary)
—Taves DR, Hasday JD, Lockwood D: Determinants of response to anorexiants, 528
Wenger T: *see Lindenbaum et al.*, 317
Wilcox HH: *see Bauer et al.*, 35
Wilke J: *see Kuhlmann et al.*, 518
Wilkins LH, Winteritz SR, Oparil S, Smith LR, Dustan HP: Lofexidine and clonidine in moderate essential hypertension, 752
Wilkinson GR: *see Verbeeck et al.*, 619
Williams RL, Upton RA, Buskin JN, Jones RM: Ketoprofen-aspirin interactions, 226
Winteritz SR: *see Wilkins et al.*, 752
Wiseman K: *see Rickels et al.*, 95
Woodcock BG, Schulz W, Kober G, Reitbrock N: Direct determination of hepatic extraction of verapamil in cardiac patients, 52

Y

- Yancovitz SR: *see Novick et al.*, 353
Yasuda H: *see Nomura et al.*, 177
Yeh KC: *see Tobert et al.*, 385
Yu VL: *see Garzone et al.*, 86

Z

- Zahrowski JJ: *see Jacobson et al.*, 487
Zal M: *see Rickels et al.*, 95
Ziegler G: *see Allonen et al.*, 653
Zilly W: *see Kuhlmann et al.*, 518
Zuraleff J: *see Garzone et al.*, 86
Zusman RM, Crow JW, Cato AE, Tolkoff-Rubin N: Effects of prostacyclin infusion in uremic patients: hematologic and hemodynamic responses, 251

Subject index

A

- Absorption, acetaminophen, and metabolism in celiac disease and Crohn's disease (Holt et al), 232
Acetabutol, addition of, to diuretics in hypertension (Gorkin et al), 739
Acetaminophen absorption and metabolism in celiac disease and Crohn's disease (Holt et al), 232
Acetylation, clonazepam, in fast and slow acetylators (Miller et al), 343
Acetylators, fast and slow, clonazepam acetylation in (Miller et al), 343
 β -Acetyl digoxin, renal excretion and plasma level of, effects of cytostatic drugs on (Kuhmann et al), 518
 α_1 -Acid glycoprotein and lidocaine disposition, relationship between, in myocardial infarction (Routledge et al), 154
Acyclovir, intravenous radioactive, disposition of (de Miranda et al), 662
Adenosine monophosphate, isoproterenol-stimulated, effects of caffeine withdrawal on (Mackenzie et al), 436
Adrenoceptor blockers, β_1 - and β_1/β_2 , antihypertensive therapy with, metabolic effects in muscle during (Frisk-Holmberg et al), 611
Age, renal disease, and oxazepam kinetics (Murray et al), 805
Agonist activity, partial, of pindolol, measurement of (Carruthers and Twum-Barima), 581
Alcohol and diazepam, onset of peak impairment after (Ellinwood et al), 534
use, short- and long-term, effect of, on phenytoin kinetics in chronic alcoholics (Sandor et al), 390
Alcoholics, chronic, phenytoin kinetics in, effect of short- and long-term alcohol use on (Sandor et al), 390
Aldose reductase inhibitor (sorbitin), orally absorbed, kinetics of (Foulds et al), 693
- Aldosterone antagonist, bioassay of new, and evaluation of simple method of quantitative comparison (McInnes et al), 218
Aldosteronism, primary, alternative therapy for: triamterene-thiazide combination (Ganguly and Weinberger), 246
Aluminum and calcium salts and furosemide, interaction of atenolol with (Kirch et al), 429
American Society for Clinical Pharmacology and Therapeutics, notes of, 147, 281, 704, 817
Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride (Waldorff et al), 172
d-Amphetamine, effects of: cigarette smoking and subjective response (Henningfield and Griffiths), 497
Anorexiants, determinants of response to (Weintraub et al), 528
Antacids, effect of, on bioavailability of diflunisal in fasting and postprandial states (Tobert et al), 385
Antagonist(s), aldosterone, bioassay of new, and evaluation of simple method of quantitative comparison (McInnes et al), 218
prananol and sotalol as, of isoproterenol-enhanced physiologic tremor (Pickles et al), 303
Anticonvulsant therapy, long-term, and intestinal calcium absorption (Wahl et al), 506
Antihypertensive therapy with β_1 - and β_1/β_2 -adrenoceptor blockers, metabolic effects in muscle during (Frisk-Holmberg et al), 611
Antipyrine clearance, ethanol and (Døssing and Andreasen), 101
kinetics in children, effects of growth hormone on (Rifkind et al), 127
and warfarin disposition in patient with idiopathic hypoalbuminemia (Pirola et al), 810
Arousal, morphinelike, by methadone during sleep (Pickworth et al), 796
Artery spasm, coronary, patients with, verapamil kinetics in normal subjects and (Freedman et al), 644
Artifactual nature of heparin-induced drug protein-binding alterations (Brown et al), 636

July, pp. 1-148; August, pp. 149-282; September, pp. 283-428;
October, pp. 429-580; November, pp. 581-708; December, pp.
709-838.

- Ascites, hepatic cirrhosis with, furosemide kinetics in patients with (Fuller et al), 461
Aspirin-ketoprofen interactions (Williams et al), 226
Atenolol, interaction of, with furosemide and calcium and aluminum salts (Kirch et al), 429
Atrial fibrillation, chronic, verapamil disposition kinetics in (Kates et al), 44
Attitudes, negative, medication acceptance despite: estrogen patient package insert (Weintraub et al), 149 (Commentary)

B

- Barbiturate and hypnotic withdrawal by multiple oral phenobarbital loading dose technique (Robinson et al), 71
Beta blockade, assessment of, with propranolol (Hager et al), 283
—blocking effect of single oral doses of carteolol (Stoll et al), 605
Binding, protein-, alterations, heparin-induced drug, artifactual nature of (Brown et al), 636
Bioassay of new aldosterone antagonist and evaluation of simple method of quantitative comparison (McInnes et al), 218
Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate (Nahata and Powell), 368
of diflunisal, effect of antacids on, in fasting and postprandial states (Tobert et al), 385
digoxin, during quinidine administration (Hager et al), 594
low oral, of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension (Bobik et al), 673
propranolol, food-induced increase in—relationship to protein and effects on metabolites (Walle et al), 790
Biostatistics, clinical, LVI. T test and basic ethos of parametric statistical inference (Conclusion) (Feinstein), 133 (Clinical biostatistics)
LVII. Glossary of neologisms in quantitative clinical science (Feinstein), 564
Blockade, beta, assessment of, with propranolol (Hager et al), 283
Blocker(s), β_1 - and β_1/β_2 -adrenoceptor, antihypertensive therapy with, metabolic effects in muscle during (Frisk-Holmberg et al), 611
—treated, β -, and hyperadrenergic vasodilator-treated patients, clonidine and prazosin effects in (Mitchell and Pettinger), 297
Blocking, beta-, effect of, of single oral doses of carteolol (Stoll et al), 605
Blood cell, red, sodium and potassium after hydrochlorothiazide (Walter), 373
loss, fecal, and platelet function, effects of diflunisal on (Green et al), 378
Body mass, lean, serum creatinine concentration based on, prediction of creatinine clearance from (Hallynck et al), 414

- Brotizolam, novel hypnotic, pharmacoencephalographic study of (Fink and Irwin), 336

C

- Caffeine withdrawal, effects of, on isoproterenol-stimulated cyclic adenosine monophosphate (Mackenzie et al), 436
Calcium absorption, intestinal, long-term anticonvulsant therapy and (Wahl et al), 506
and aluminum salts and furosemide, interaction of atenolol with (Kirch et al), 429
Cancer patients, morphine kinetics in (Säwe et al), 629
Cardiac effects of pergolide (Leibowitz et al), 719
patients, direct determination of hepatic extraction of verapamil extraction in (Woodcock et al), 52
and systemic hemodynamic interactions between clonidine and minoxidil (Velasco et al), 158
Cardiopulmonary bypass, plasma propranolol before, during, and after (Plachetka et al), 745
Carteolol, beta-blocking effect of single oral doses of (Stoll et al), 605
Cefonicid, kinetics and renal handling of (Pitkin et al), 587
Ceforanide kinetics (Estey et al), 398
in renal insufficiency (Hawkins et al), 468
Celiac disease and Crohn's disease, acetaminophen absorption and metabolism in (Holt et al), 232
Cephalosporins, comparisons with other: steady-state moxalactam kinetics (Garzone et al), 86
Children, antipyrene kinetics in, effects of growth hormone on (Rifkind et al), 127
Chloramphenicol, bioavailability and clearance of, after intravenous chloramphenicol succinate (Nahata and Powell), 368
Cigarette smoking and subjective response: effects of d-amphetamine (Henningfield and Griffiths), 497
and theophylline clearance and metabolism (Grygiel and Birkett), 491
Cimetidine, comparison with, intravenous dose studies and, II. Ranitidine kinetics and dynamics (Lebert et al), 545
elevation of steady-state diazepam levels by (Klotz and Reimann), 513
Cirrhosis, hepatic, with ascites, furosemide kinetics in patients with (Fuller et al), 461
Cirrhotic and normal subjects, presystemic metabolism of meperidine to normeperidine in (Pond et al), 183
Clearance and bioavailability of chloramphenicol after intravenous chloramphenicol succinate (Nahata and Powell), 368
creatinine, prediction of, from serum creatinine concentration based on lean body mass (Hallynck et al), 414

- Clearance—cont'd
 ethanol and antipyryne (Døssing and Andreasen), 101
 first-pass hepatic, of propranolol, reduction of, by food (McLean et al), 31
 meperidine, and normeperidine formation, effect of phenytoin on (Pond and Kretschmar), 680
 and metabolism, theophylline, cigarette smoking and (Grygiel and Birkett), 491
 reduced verapamil, during long-term oral administration (Shand et al), 701
 renal digoxin, maturation and (Linday et al), 735
- Clinical biostatistics LVI. t Test and basic ethos of parametric statistical inference (Conclusion) (Feinstein), 133 (Clinical biostatistics)
- LVII. Glossary of neologisms in quantitative clinical science (Feinstein), 564
- Pharmacology and Therapeutics, American Society for: *see* American Society for Clinical Pharmacology and Therapeutics
- Clobazam and diazepam in anxiety (Rickels et al), 95
- Clodronate kinetics and dynamics (Conrad and Lee), 114
- Clonazepam acetylation in fast and slow acetylators (Miller et al), 343
- Clonidine concentration, plasma, and pharmacologic effect (Hogan et al), 729
- intravenous, short-term effects of, in congestive heart failure (Giles et al), 724
- and lofexidine in moderate essential hypertension (Wilkins et al), 752
- and minoxidil, systemic and hemodynamic interactions between (Velasco et al), 158
- and prazosin effects in hypernoradrenergic vasodilator-treated and β -blocker-treated patients (Mitchell and Pettinger), 297
- Congestive heart failure, effect of furosemide in (Nomura et al), 177
- short-term effects of intravenous clonidine in (Giles et al), 724
- Coronary artery spasm, patients with, verapamil kinetics in normal subjects and (Freedman et al), 644
- Cotinine and nicotine concentrations, plasma, in habitual smokeless tobacco users (Gritz et al), 201
- Creatinine clearance, prediction of, from serum creatinine concentration based on lean body mass (Hallynck et al), 414
- Crohn's disease and celiac disease, acetaminophen absorption and metabolism in (Holt et al), 232
- Cytostatic drugs, effects of, on plasma level and renal excretion of β -acetyldigoxin (Kuhlmann et al), 518
- D*
- Debrisoquine hydroxylation, polymorphic, relationship to: E- and Z-10-hydroxylation of nortriptyline (Mellström et al), 189
- Decarboxylase, ornithine, irreversible inhibitor of: kinetics of α -defluoromethylornithine (Haegele et al), 210
- Diazepam and clobazam in anxiety (Rickels et al), 95
- levels, steady-state, elevation of, by cimetidine (Klotz and Reimann), 513
- onset of peak impairment after, and after alcohol (Ellinwood et al), 534
- Diclofenac, effects of, on lithium kinetics (Reimann and Fröhlich), 348
- Dietary saccharin kinetics (Colburn et al), 559
- Diethylcarbamazine disposition in patients with onchocerciasis (Edwards et al), 551
- Diflunisal, bioavailability of, effect of antacids on, in fasting and postprandial states (Tobert et al), 385
- effects of, on platelet function and fecal blood loss (Green et al), 378
- α -Defluoromethylornithine, kinetics of: irreversible inhibitor of ornithine decarboxylase (Haegele et al), 210
- Digoxin bioavailability during quinidine administration (Hager et al), 594
- clearance, renal, maturation and (Linday et al), 735
- dynamics and kinetics, amiloride-induced changes in: abolition of digoxin-induced inotropism with amiloride (Waldorff et al), 172
- urinary excretion, lack of difference in, with two intravenous infusion rates (Lindenbaum et al), 317
- verapamil interaction (Pedersen et al), 313
- Dihydroergotamine in idiopathic orthostatic hypotension: short-term intramuscular and long-term oral therapy (Fouad et al), 782
- low oral bioavailability of, and first-pass extraction in patients with orthostatic hypotension (Bobik et al), 673
- Disposition: *see* specific drug
- Diuretic(s) in hypertension, addition of acebutolol to (Gorkin et al), 739
- and propranolol, effects of, on plasma lipoprotein lipids (Bauer et al), 35
- Dose-response studies of quazepam (Kales et al), 194
- Drug(s): *see also* specific drug name
- reactions, adverse, method for estimating probability of (Naranjo et al), 239
- suicide inhibitors as potential (Sjoerdema et al), 3 (Commentary)
- E*
- E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189
- Effusion, pericardial, and minoxidil: idiosyncratic reaction (Reichgott), 64
- Elimination, high intrinsic clearance drug, mechanism of food-related alterations in: effect of food on lidocaine kinetics (Elvin et al), 455
- Theophylline, depression of, by erythromycin (Renton et al), 422

Enzyme inhibition, long-term converting, hormonal responses to, in hypertensive patients (Ogihara et al), 328
suicide, inhibitors, as potential drugs (Sjoerdsma), 3 (Commentary)
Erythrocyte sodium and phosphate transport, effect of ouabain and furosemide on (Walter), 709
Erythromycin, depression of theophylline elimination by (Renton et al), 422
Essential hypertension, long-term hemodynamic and metabolic effects of trimazosin in (Chrysant et al), 600
mild, short- and long-term therapy of, with timolol (Harris et al), 765
moderate, lofexidine and clonidine in (Wilkins et al), 752
norepinephrine release in (FitzGerald et al), 164
Estimating probability of adverse drug reactions, method for (Naranjo et al), 239
Estrogen patient package insert: medication acceptance despite negative attitudes (Weintraub et al), 149 (Commentary)
Ethanol and antipyrene clearance (Døssing and Andreassen), 101
Ethos, basic, of parametric statistical inference, t test and (Conclusion) (Feinstein), 133 (Clinical biostatistics)
Excretion, digoxin urinary, lack of difference in, with two intravenous infusion rates (Lindenbaum et al), 317
Exercise performance, variability of, during long-term placebo treatment (McGraw et al), 321
Extraction, first-pass, low oral bioavailability of dihydroergotamine and, in patients with orthostatic hypotension (Bobik et al), 673
hepatic, of verapamil, direct determination of, in cardiac patients (Woodcock et al), 52
no stereoselective first-pass hepatic, of propranolol (Jackman et al), 291

F

Fasting and postprandial states, effect of antacids on bioavailability of diflunisal in the (Tobert et al), 385
Fecal blood loss and platelet function, effects of diflunisal on (Green et al), 378
First-pass extraction, low oral bioavailability of dihydroergotamine and, in patients with orthostatic hypotension (Bobik et al), 673
hepatic clearance of propranolol, reduction of, by food (McLean et al), 31
extraction, no stereoselective, of propranolol (Jackman et al), 291
Flurazepam, kinetics and clinical effects of, in young and elderly noninsomniacs (Greenblatt et al), 475
Food, effect of, on lidocaine kinetics: mechanism of food-related alterations in high intrinsic clearance drug elimination (Elvin et al), 455

Food—cont'd
-induced increase in propranolol bioavailability—relationship to protein and effects on metabolites (Walle et al), 790
reduction of first-pass hepatic clearance of propranolol by (McLean et al), 31
Furosemide and calcium and aluminum salts, interaction of atenolol with (Kirch et al), 429
effect of, in congestive heart failure (Nomura et al), 177
kinetics and dynamics after kidney transplant (Smith et al), 105
in patients with hepatic cirrhosis with ascites (Fuller et al), 461
and ouabain, effect of, on erythrocyte sodium and phosphate transport (Walter), 709

G

Glossary of neologisms in quantitative clinical science (Feinstein), 564 (Clinical biostatistics)
Glycoprotein, α_1 -acid, and lidocaine disposition relationship between, in myocardial infarction (Routledge et al), 154
Growth hormone, effects of, on antipyrene kinetics in children (Rifkind et al), 127

H

Heart failure, congestive, effect of furosemide in (Nomura et al), 177
short-term effects of intravenous clonidine in (Giles et al), 724
refractory, patients with, dynamic responses to continuous use of prazosin and hydralazine in (Elkayam et al), 23
Hematologic and hemodynamic responses: effects of protacyclin infusion in uremic patients (Zusman et al), 251
Hemodialysis, decreased quinidine plasma protein binding during (Kessler and Perez), 121
moxalactam kinetics in (Jacobson et al), 487
and uremia, effects of, on lorazepam disposition (Kampf et al), 77
Hemodynamic and hematologic responses: effects of protacyclin infusion in uremic patients (Zusman et al), 251
interactions, systemic and cardiac, between clonidine and minoxidil (Velasco et al), 158
and metabolic effects, long-term, of trimazosin in essential hypertension (Chrysant et al), 600
Heparin-induced drug protein-binding alterations, artifactual nature of (Brown et al), 636
Hepatic cirrhosis with ascites, furosemide kinetics in patients with (Fuller et al), 461
clearance, first-pass, of propranolol, reduction of, by food (McLean et al), 31
extraction, direct determination of, of verapamil in cardiac patients (Woodcock et al), 52
no stereoselective first-pass, of propranolol (Jackman et al), 291

- Hepatic cirrhosis—cont'd
 monooxygenase activity and vitamin D metabolism, effect of isoniazid on (Brodie et al), 363
- Hormonal responses to long-term converting enzyme inhibition in hypertensive patients (Ogihara et al), 328
- Hydralazine, intravenous, in hypertension, determinants of response to (Shepherd et al), 773
 and prazosin, dynamic responses to continuous use of, in patients with refractory heart failure (Elkayam et al), 23
- Hydrochlorothiazide, red blood cell sodium and potassium after (Walter), 373
- Hydroxylation, E- and Z-10-, of nortriptyline: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189
- Hypnoradrenergic vasodilator-treated and β -blocker-treated patients, clonidine and prazosin effects in (Mitchell and Pettinger), 297
- Hypertension, determinants of response to intravenous hydralazine in (Shepherd et al), 773
 diuretics in, addition of acebutolol to (Gorkin et al), 739
 essential, long-term hemodynamic and metabolic effects of trimazosin in (Chysant et al), 600
 norepinephrine release in (FitzGerald et al), 164
 mild essential, short- and long-term therapy of, with timolol (Harris et al), 765
 moderate essential, lofexidine and clonidine in (Wilkins et al), 752
 prazosin dynamics in: relationship to plasma concentration (Seideman et al), 447
 kinetics in (Grahnén et al), 439
- Hypertensive patients, hormonal responses in, to long-term converting enzyme inhibition (Ogihara et al), 328
- Hypnosedative and barbiturate withdrawal by multiple oral phenobarbital loading dose technique (Robinson et al), 71
- Hypnotic, novel, pharmacoecephalographic study of brotizolam (Fink and Irwin), 336
- Hypoalbuminemia, idiopathic, antipyryne and warfarin disposition in patient with (Piroli et al), 810
- Hypotension, idiopathic orthostatic, dihydroergotamine in: short-term intramuscular and long-term oral therapy (Fouad et al), 782
 orthostatic, patients with, low oral bioavailability of dihydroergotamine and first-pass extraction in (Bobik et al), 673
- I
- Idiopathic hypoalbuminemia, antipyryne and warfarin disposition in patient with (Piroli et al), 810
 orthostatic hypotension, dihydroergotamine in: short-term intramuscular and long-term oral therapy (Fouad et al), 782
- Idiosyncratic reaction: minoxidil and pericardial effusion (Reichgott), 64
- Infarction, myocardial, relationship between α_1 -acid glycoprotein and lidocaine disposition in (Routledge et al), 154
- Infusion, prostacyclin, effects of, in uremic patients: hematologic and hemodynamic responses (Zusman et al), 251
- rates, intravenous, lack of difference in digoxin urinary excretion with (Lindenbaum et al), 317
- Inhibition, long-term converting enzyme, hormonal responses to, in hypertensive patients (Ogihara et al), 328
- Inhibitor(s), orally absorbed aldose reductase (sorbinil), kinetics of (Foulds et al), 693
 irreversible, of ornithine decarboxylase: kinetics of α -difluoromethylornithine (Haegele et al), 210
 suicide enzyme, as potential drugs (Sjoerdsma), 3 (Commentary)
- Inotropic with amiloride, abolition of digoxin-induced: amiloride-induced changes in digoxin dynamics and kinetics (Waldorff et al), 172
- Insert, estrogen patient package: medication acceptance despite negative attitudes (Weintraub et al), 149 (Commentary)
- Intestinal calcium absorption, long-term anticonvulsant therapy and (Wahl et al), 506
- Intramuscular therapy, short-term, and long-term oral: dihydroergotamine in idiopathic orthostatic hypotension (Fouad et al), 782
- Intravenous chloramphenicol succinate, bioavailability and clearance of chloramphenicol after (Nahata and Powell), 368
 clonidine, short-term effects of, in congestive heart failure (Giles et al), 724
- dose studies and comparison with cimetidine, II. Ranitidine kinetics and dynamics (Lebert et al), 545
- hydralazine in hypertension, determinants of response to (Shepherd et al), 773
 infusion rates, two, lack of difference in digoxin urinary excretion with (Lindenbaum et al), 317
 radioactive acyclovir, disposition of (de Miranda et al), 662
- Isoniazid, effect of, on vitamin D metabolism and hepatic monooxygenase activity (Brodie et al), 363
- Isoproterenol-enhanced physiologic tremor, propranolol and sotalol as antagonists of (Pickles et al), 303
 -stimulated cyclic adenosine monophosphate, effects of caffeine withdrawal on (Mackenzie et al), 436
- K
- Ketoprofen-aspirin interactions (Williams et al), 226
 Kinetics: see specific drug

L

- Labetalol and methyldopa, effects of, on renal function (Cruz et al), 57
Lidocaine disposition and α_1 -acid glycoprotein, relationship between, in myocardial infarction (Routledge et al), 154
kinetics, effect of food on: mechanism of food-related alterations in high intrinsic clearance drug elimination (Elvin et al), 455
Lipids, plasma lipoprotein, effects of diuretic and propranolol on (Bauer et al), 35
Lipoprotein lipids, plasma, effects of diuretic and propranolol on (Bauer et al), 35
Lithium kinetics, effects of diclofenac on (Reimann and Frölich), 348
Liver disease, chronic, methadone disposition in patients with (Novick et al), 353
Loading dose technique, phenobarbital, multiple oral, barbiturate and hypnotic withdrawal by (Robinson et al), 71
Lofexidine and clonidine in moderate essential hypertension (Wilkins et al), 752
Lormetazepam disposition, effects of uremia and hemodialysis on (Kampf et al), 77

M

- Maternal smoking, sensitivity of human placental monooxygenase activity to (Manchester and Jacoby), 687
Maturation and renal digoxin clearance (Linday et al), 735
Medication acceptance despite negative attitudes: estrogen patient package insert (Weintraub et al), 149 (Commentary)
Meperidine clearance and normeperidine formation, effect of phenytoin on (Pond and Kretschmar), 680
disposition in man: influence of urinary pH and route of administration (Verbeeck et al), 619
presystemic metabolism of, to normeperidine in normal and cirrhotic subjects (Pond et al), 183
Metabolic effects in muscle during antihypertensive therapy with β_1 - and β_1/β_2 -adrenoceptor blockers (Frisk-Holmberg et al), 611
and hemodynamic effects, long-term, of trimazosin in essential hypertension (Chrysant et al), 600
Metabolism, acetaminophen absorption and, in celiac disease and Crohn's disease (Holt et al), 232
and clearance, theophylline, cigarette smoking and (Grygiel and Birkett), 491
presystemic, of meperidine to normeperidine in normal and cirrhotic subjects (Pond et al), 183
vitamin D, and hepatic monooxygenase activity, effect of isoniazid on (Brodie et al), 363

- Metabolite(s), effects on, and protein, relationship to: food-induced increase in propranolol bioavailability (Walle et al), 790
kinetics, salicylate, after several salicylates (Bochner et al), 266

- Methadone disposition in patients with chronic liver disease (Novick et al), 353
morphinelike arousal by, during sleep (Pickworth et al), 796

- Methyldopa and labetalol, effects of, on renal function (Cruz et al), 57
Midazolam kinetics (Allonen et al), 653
Minoxidil and clonidine, systemic and hemodynamic interactions between (Velasco et al), 158
and pericardial effusion: idiosyncratic reaction (Reichgott), 64

- Monooxygenase activity, hepatic, and vitamin D metabolism, effect of isoniazid on (Brodie et al), 363
human placental, sensitivity of, to maternal smoking (Manchester and Jacoby), 687
Monophosphate, adenosine, isoproterenol-stimulated, effects of caffeine withdrawal on (Mackenzie et al), 436

- Morphine kinetics in cancer patients (Säwe et al), 629
Morphinelike arousal by methadone during sleep (Pickworth et al), 796
Moxalactam kinetics in hemodialysis (Jacobson et al), 487
steady-state: comparisons with other cephalosporins (Garzone et al), 86

- Muscle, metabolic effects in, during antihypertensive therapy with β_1 - and β_1/β_2 -adrenoceptor blockers (Frisk-Holmberg et al), 611

- Myocardial infarction, relationship between α_1 -acid glycoprotein and lidocaine disposition in (Routledge et al), 154

N

- Neologisms, glossary of, in quantitative clinical science (Feinstein), 564 (Clinical biostatistics)
- Nicotine and cotinine concentrations, plasma, in habitual smokeless tobacco users (Gritz et al), 201
- Noninsomniacs, young and elderly, kinetics and clinical effects of flurazepam in (Greenblatt et al), 475
- Norepinephrine release in essential hypertension (FitzGerald et al), 164
- Normeperidine formation, and meperidine clearance, effect of phenytoin on (Pond and Kretschmar), 680
presystemic metabolism of meperidine to, in normal and cirrhotic subjects (Pond et al), 183
- Nortriptyline, E- and Z-10-hydroxylation of: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189

O

- Onchoceriasis, diethylcarbamazine disposition in patients with (Edwards et al), 551
 Oral administration, long-term, reduced verapamil during (Shand et al), 701
 bioavailability, low, of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension (Bobik et al), 673
 dose(s) of carteolol, single, beta-blocking effect of (Stoll et al), 605
 studies, I. Ranitidine kinetics and dynamics (Lebert et al), 539
 propranolol, central ventilatory depression by (Campbell et al), 758
 therapy, long-term, and short-term intramuscular: dihydroergotamine in idiopathic orthostatic hypotension (Fouad et al), 782
 Ornithine decarboxylase, irreversible inhibitor of: kinetics of α -difluoro methylornithine (Haegele et al), 210
 Orthostatic hypotension, idiopathic, dihydroergotamine in: short-term intramuscular and long-term oral therapy (Fouad et al), 782
 patients with, low oral bioavailability of dihydroergotamine and first-pass extraction in (Bobik et al), 673
 Ouabain and furosemide, effect of, on erythrocyte sodium and phosphate transport (Walter), 709
 Oxazepam kinetics, renal disease, and age (Murray et al), 805

P

- Parametric statistical inference, basic ethos of, t test and (Conclusion) (Feinstein), 133 (Clinical biostatistics)
 Patient package insert, estrogen: medication acceptance despite negative attitudes (Weintraub et al), 149 (Commentary)
 Penicillamine kinetics in normal subjects (Bergstrom et al), 404
 Peptides, isolation of, from uremic plasma that inhibit phenytoin binding to normal plasma proteins (Kinniburgh and Boyd), 276
 Pergolide, cardiac effects of (Leibowitz et al), 719
 physiologic disposition of (Rubin et al), 258
 Pericardial effusion, and minoxidil: idiosyncratic reaction (Reichgott), 64
 pH, urinary, and route of administration, influence of: meperidine disposition in man (Verbeek et al), 619
 Pharmacencephalographic study of brotizolam, novel hypnotic (Fink and Irwin), 336
 Pharmacology, Clinical, and Therapeutics, American Society for: see American Society for Clinical Pharmacology and Therapeutics
 Phenobarbital loading dose technique, multiple oral, barbiturate and hypnotosedative withdrawal by (Robinson et al), 71
- Phenytoin binding to normal plasma proteins, isolation of peptides from uremic plasma that inhibit (Kinniburgh and Boyd), 276
 effect of, on meperidine clearance and normeperidine formation (Pond and Kretschmar), 680
 kinetics in chronic alcoholics, effect of short- and long-term alcohol use on (Sandor et al), 390
 Phosphate transport and erythrocyte sodium, effect of ouabain and furosemide on (Walter), 709
 Physiologic disposition of pergolide (Rubin et al), 258
 tremor, isoproterenol-enhanced, propranolol and sotalol as antagonists of (Pickles et al), 303
 Pindolol, measurement of partial agonist activity of (Carruthers and Twum-Barima), 581
 Placebo treatment, long-term, variability of exercise performance during (McGraw et al), 321
 Placental monooxygenase activity, human, sensitivity of, to maternal smoking (Manchester and Jacoby), 687
 Plasma clonidine concentration and pharmacologic effect (Hogan et al), 729
 concentration, relationship to: prazosin dynamics in hypertension (Seideman et al), 447
 lipoprotein lipids, effects of diuretic and propranolol on (Bauer et al), 35
 nicotine and cotinine concentrations in habitual smokeless tobacco users (Gritz et al), 201
 propranolol before, during, and after cardiopulmonary bypass (Plachetka et al), 745
 protein binding, quinidine, decreased, during hemodialysis (Kessler and Perez), 121
 uremic, isolation of peptides from, that inhibit phenytoin binding to normal plasma proteins (Kinniburgh and Boyd), 276
 Platelet function and fecal blood loss, effects of diflunisal on (Green et al), 378
 Polymorphic debrisoquine hydroxylation, relationship to: E- and Z-10-hydroxylation of nortriptyline (Mellström et al), 189
 Postprandial and fasting states, effect of antacids on the bioavailability of diflunisal in (Tobert et al), 385
 Potassium and sodium, red blood cell, after hydrochlorothiazide (Walter), 373
 Prazosin and clonidine effects in hypernoradrenergic vasodilator-treated and β -blocker-treated patients (Mitchell and Pettinger), 297
 dynamics in hypertension: relationship to plasma concentration (Seideman et al), 447
 and hydralazine, dynamic responses to continuous use of, in patients with refractory heart failure (Elkayam et al), 23
 kinetics in hypertension (Grahnen et al), 439
 Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects (Pond et al), 183

Propranolol, assessment of beta blockade with (Hager et al), 283
bioavailability, food-induced increase in—relationship to protein and effects on metabolites (Walle et al), 790
and diuretic, effects of, on plasma lipoprotein lipids (Bauer et al), 35
no stereoselective first-pass hepatic extraction of (Jackman et al), 291
oral, central ventilatory depression by (Campbell et al), 758
plasma, before, during, and after cardiopulmonary bypass (Plachetka et al), 745
reduction of first-pass hepatic clearance of, by food (McLean et al), 31
and sotalol as antagonists of isoproterenol-enhanced physiologic tremor (Pickles et al), 303
Prostacyclin infusion, effects of, in uremic patients: hematologic and hemodynamic responses (Zusman et al), 251
Protein-binding alterations, heparin-induced drug, artifactual nature of (Brown et al), 636
decreased, plasma quinidine during hemodialysis (Kessler and Perez), 121
relationship to, and effects on metabolites,—food-induced increase in propranolol bioavailability (Walle et al), 790

Q

Quantitative comparison, evaluation of simple method of and bioassay of new aldosterone antagonist (McInnes et al), 218
Quazepam, dose-response studies of (Kales et al), 194
Quinidine plasma protein binding, decreased, during hemodialysis (Kessler and Perez), 121

R

Radioactive acyclovir, intravenous, disposition of (de Miranda et al), 662
Ranitidine kinetics and dynamics. I. Oral dose studies (Lebert et al), 539
II. Intravenous dose studies and comparison with cimetidine (Lebert et al), 545
Reductase inhibitor, aldose, orally absorbed, kinetics of (sorbitol) (Foulds et al), 693
Renal digoxin clearance, maturation and (Lindsay et al), 735
disease, age, and oxazepam kinetics (Murray et al), 805
excretion and plasma level of β -acetyldigoxin, effects of cytostatic drugs on (Kuhlmann et al), 518
function, effects of labetalol and methyldopa on (Cruz et al), 57
handling and kinetics of cefonicid (Pitkin et al), 587
insufficiency, ceforanide kinetics in (Hawkins et al), 468

Route of administration and urinary pH, influence of: meperidine disposition in man (Verbeeck et al), 619

S

Saccharin kinetics, dietary (Colburn et al), 559
Salicylate metabolite kinetics after several salicylates (Bochner et al), 266
Serum creatinine concentration based on lean body mass, prediction of creatinine clearance from (Hallynck et al), 414
Significance of significant, on (Modell), 1 (Editorial)
Sleep, morphinelike arousal by methadone during (Pickworth et al), 796
Smokeless tobacco users, habitual, plasma nicotine and cotinine concentrations in (Gritz et al), 201
Smoking, cigarette, and subjective response: effects of *d*-amphetamine (Henningfield and Griffiths), 497
and theophylline clearance and metabolism (Grygiel and Birkett), 491
maternal, sensitivity of human placental monooxygenase activity to (Manchester and Jacoby), 687
Sodium, erythrocyte, and phosphate transport, effect of ouabain and furosemide on (Walter), 709
and potassium, red blood cell, after hydrochlorothiazide (Walter), 373
Sorbitol, kinetics of orally absorbed aldose reductase inhibitor (Foulds et al), 693
Sotalol and propranolol as antagonists of isoproterenol-enhanced physiologic tremor (Pickles et al), 303
Spasm, coronary artery, patients with, verapamil kinetics in normal subjects and (Freedman et al), 644
Statistical inference, parametric, basic ethos of, t test and (Conclusion) (Feinstein), 133 (Clinical biostatistics)
Steady-state diazepam levels, elevation of, by cimetidine (Klotz and Reimann), 513
moxalactam kinetics: comparisons with other cephalosporins (Garzone et al), 86
Stereoselective first-pass hepatic extraction, no, of propranolol (Jackman et al), 291
Succinate, chloramphenicol, intravenous, bioavailability and clearance of chloramphenicol after (Nahata and Powell), 368
Suicide enzyme inhibitors as potential drugs (Sjoerdsma), 3 (Commentary)
Systemic and cardiac hemodynamic interactions between clonidine and minoxidil (Velasco et al), 158

T

t Test and basic ethos of parametric statistical inference (Conclusion) (Feinstein), 133 (Clinical biostatistics)

Theophylline clearance and metabolism, cigarette smoking and (Grygiel and Birkett), 491
 elimination, depression of, by erythromycin (Rennert et al), 422

Therapeutics, Clinical Pharmacology and, American Society for: *see* American Society for Clinical Pharmacology and Therapeutics

Therapy, alternative, for primary aldosteronism: triamterene-thiazide combination (Ganguly and Weinberger), 246

short-term intramuscular and long-term oral: dihydroergotamine in idiopathic orthostatic hypotension (Fouad et al), 782

and long-term, of mild essential hypertension with timolol (Harris et al), 765

Thiazide-triamterene combination: alternative therapy for primary aldosteronism (Ganguly and Weinberger), 246

Timolol, short- and long-term therapy of mild essential hypertension with (Harris et al), 765

Tobacco users, habitual smokeless, plasma nicotine and cotinine concentrations in (Gritz et al), 201

Transplant, kidney, furosemide kinetics and dynamics after (Smith et al), 105

Tremor, isoproterenol-enhanced physiologic, propranolol and sotalol as antagonists of (Pickles et al), 303

Triamterene-thiazide combination: alternative therapy for primary aldosteronism (Ganguly and Weinberger), 246

Trimazosin, long-term hemodynamic and metabolic effects of, in essential hypertension (Chrysant et al), 600

U

Uremia and hemodialysis, effects of, on lorazepam disposition (Kampf et al), 77

Uremic patients, effects of prostacyclin infusion in: hematologic and hemodynamic responses (Zusman et al), 251

plasma, isolation of peptides from, that inhibit phenytoin binding to normal plasma proteins (Kinniburgh and Boyd), 276

Urinary excretion, digoxin, lack of difference in, with two intravenous infusion rates (Lindenbaum et al), 317

pH and route of administration, influence of: meperidine disposition in man (Verbeeck et al), 619

USAN Council list of new names, 427, 579, 707, 819

V

Vasodilator-treated, hypernoradrenergic, and β -blocker-treated patients, clonidine and prazosin effects in (Mitchell and Pettinger), 297

Ventilatory depression, central, by oral propranolol (Campbell et al), 758

Verapamil clearance, reduced, during long-term oral administration (Shand et al), 701

-digoxin interaction (Pedersen et al), 313

disposition kinetics in chronic atrial fibrillation (Kates et al), 44

hepatic extraction of, direct determination of, in cardiac patients (Woodcock et al), 52

kinetics in normal subjects and patients with coronary artery spasm (Freedman et al), 644

Vitamin D metabolism and hepatic monooxygenase activity, effect of isoniazid on (Brodie et al), 363

W

Warfarin and antipyrine disposition in patient with idiopathic hypoalbuminemia (Pirola et al), 810

Withdrawal, barbiturate and hypnotic, by multiple oral phenobarbital loading dose technique (Robinson et al), 71

caffeine, effects of, on isoproterenol-stimulated cyclic adenosine monophosphate (MacKenzie et al), 436

Z

Z-10-hydroxylation, E- and, of nortriptyline: relationship to polymorphic debrisoquine hydroxylation (Mellström et al), 189

